Form D · Biotechnology
Immuno Cancer Biotherapeutics, Inc.
Canton, SD · CIK 0002158173
Offering snapshot reported Oct 15, 2026 · SEC filing
- Reported sold
- $75K Indefinite offering
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 15, 2026 | Initial | $75,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-601448
SAFE (Simple Agreement for Future Equity)
Source: Form D, filed Oct 15, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Collins | Director |
| James Robl | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
48351 277 Th St
Canton, SD, 57013-5507
Phone: 6053107663
Canton, SD, 57013-5507
Phone: 6053107663